

**REMARKS**The Claims

Claims 82-92 are currently pending in the application. The claims as set forth above include all claim amendments presented by Applicant in the Response to Final Office Action mailed August 11, 2004.

In an advisory action dated December 20, 2004, the Examiner entered the proposed claim amendments but indicated that they did not place the application in condition for allowance.

Claim 82 has been amended to delete recitation of an antibody that is obtained by immunization of a transgenic rodent capable of producing human antibodies and to add the recitation that the antibody inhibits osteoclast formation. Support for this amendment is found at p.18, lines 4-15 of the specification.

Rejection under 35 U.S.C.112


The rejection of Claims 82-92 under 35 U.S.C. 112, first paragraph, was maintained as the specification allegedly is not enabling for the claimed human monoclonal antibodies because the specification fails to teach how to make a transgenic animal that produces human antibodies and fails to teach the steps for making human antibodies by immunizing a transgenic animal. The Examiner also alleges that the production of human antibodies is unpredictable and undeveloped.

While not acquiescing to the rejection and solely to advance prosecution, Applicant has deleted recitation of an antibody that is obtained by immunization of a transgenic rodent capable of producing human antibodies. The rejection may be withdrawn.

**CONCLUSION**

Claims 82-92 are in condition for allowance and an early notice thereof is solicited.

Respectfully submitted,



Robert B. Winter  
Attorney/Agent for Applicant  
Registration No.: 34,458  
Phone: (206) 265-2425  
Date: March 11, 2005

Please send all future correspondence to:

US Patent Operations/RBW  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799